FDA Approves Cosentyx for Polymyalgia Rheumatica, Wilserdly for ER-Positive ESR1-Mutated Advanced Breast Cancer
Key Takeaways
- Secukinumab offers a new steroid-sparing option in polymyalgia rheumatica, a disease with frequent relapse and meaningful glucocorticoid-associated morbidity, particularly in older adults.
- Phase III Replenish data showed secukinumab doubled sustained remission likelihood while enabling corticosteroid tapering, aligning efficacy with a central therapeutic goal in polymyalgia rheumatica management.
FDA submitted approvals for Novartis’s Cosentyx and Roche’s Wilserdly.
Two new treatments in rheumatology and oncology secured key FDA approvals this week, each addressing diseases where treatment options have remained limited for years.
Novartis wins FDA approval for Cosentyx
FDA approved Cosentyx (secukinumab) 150 mg for adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
The approval makes Cosentyx the first and only anti-interleukin-17 biologic cleared for people living with polymyalgia rheumatica, a common inflammatory disease that primarily affects adults over 50, giving physicians a new option beyond the long-term steroid use that has long served as the standard of care.1
In the U.S., approximately 966,000 people live with polymyalgia rheumatica, a disease marked by acute pain and stiffness in the shoulders, neck, and hips.1 The condition is commonly treated with steroids, but relapses are frequent, striking up to 40% of patients in the first year. Long-term steroid use carries its own risks, raising the likelihood of osteoporosis, cardiovascular disease, and diabetes. Following the approval, Cosentyx is now available as an alternative to extended steroid use, backed by more than a decade of clinical experience across immune-mediated diseases.1
Prof. John Stone, MD, MPH, professor of medicine, Harvard Medical School, Massachusetts General Hospital, and global principal investigator for the Replenish trial, says patients with polymyalgia rheumatica are at increased risk of poor outcomes related to steroids, and the prospect of months or years of additional steroids is disheartening. “The FDA approval of secukinumab in PMR marks a significant advancement for patients and physicians. Patients with PMR are at increased risk of poor outcomes related to steroids, and the prospect of months or years of additional steroids is disheartening,” says Stone. “For too long, treatment options beyond glucocorticoids have been limited. In the Phase III Replenish trial, secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment.”
Roche gains FDA approval for Wilserdly
FDA also approved Wilserdly (giredestrant) in combination with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or progressed on at least one endocrine-based regimen in the metastatic setting, as detected by an FDA-authorized test. The approval addresses a significant unmet need as up to 40% of patients with hormone receptor-positive metastatic breast cancer develop ESR1 mutations that drive resistance and disease progression.
"For patients with ESR1-mutated advanced breast cancer, the development of resistance to endocrine therapy remains a substantial challenge - often requiring more intensive treatment,” says Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “By pairing potent oestrogen receptor degradation with everolimus, Wilserdly offers a targeted, all-oral regimen that significantly delays disease progression and allows advanced breast cancer patients to take their treatment from home.”
The approval rests on primary endpoint data from the Phase III Evera breast cancer study. In adult patients with ESR1-mutated, estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing after prior cyclin-dependent kinase 4/6 inhibitor therapy, the all-oral combination of Wilserdly plus everolimus significantly prolonged progression-free survival, achieving a 62% reduction in the risk of disease progression or death compared to standard endocrine therapy plus everolimus, with a stratified hazard ratio of 0.38.2
Dr Erica L. Mayer, director of breast cancer clinical research at the Dana-Farber Cancer Institute, says patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow. “Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow,” says Dr. Mayer. “The evERA trial demonstrates that the oral giredestrant combination regimen directly targets the primary genomic drivers of resistance, offering patients prolonged disease control through a fully oral therapeutic option.”
Roche has also submitted a New Drug Application for Wilserdly as an adjuvant treatment for adults with estrogen receptor-positive, HER2-negative, stage I, II, and III breast cancer at intermediate to high risk of recurrence, based on the Phase III Lidera breast cancer study, which was accepted under Priority Review.2 FDA has set a Prescription Drug User Fee Act date of November 30, 2026, and if approved, this would represent the first new adjuvant endocrine therapy in over 20 years, with the potential to establish a new standard of care in this setting.2
Sources
- Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR) Novartis November 17, 2026,
https://www.novartis.com/news/media-releases/novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-people-polymyalgia-rheumatica-pmr - FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer Roche November 15, 2026,
https://www.roche.com/media/releases/med-cor-2026-11-16b
Related to this article






